30
Views
2
CrossRef citations to date
0
Altmetric
Review

Update on GPIIb/IIIa antagonists

, , , , &
Pages 1173-1188 | Published online: 02 Mar 2005
 

Abstract

Since platelet aggregation is implicated in many pathological situations such as myocardial infarction, stroke, unstable angina and coronary artery disease, potent and safe antiplatelet agents would be useful for treating and preventing these diseases. Exposure of glycoprotein (GP)IIb/IIIa is the final common pathway leading to platelet activation and aggregate formation. Thus, the development of agents acting on this complex is an active area of research. Indeed, three GPIIb/IIIa antagonists are currently marketed but can only be intravenously administrated. Therefore, efforts are made to discover orally-active agents of this class, in order to use them for treatment of chronic disease or prevention of cardiovascular events. Although some clinical evaluation of orally-active compounds gave disappointing and discouraging results, research is still conducted to find compounds characterised by a better binding profile. This review describes 16 patents on new GPIIb/IIIa antagonists and more than 40 molecules characterised by strong activity against GPIIb/IIIa.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.